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with regard to in vitro resistance, SCCmec type, frequency of pvl
gene and MLST type.
There have rare report about molecular characteristic of CA-
MRSA infections in children from China, this prospective study
was undertaken in order to characterize the molecular char-
acteristic of CA-MRSA in children in China. We collected 99
CA-MRSA isolates from 8 hospitals in 7 cities in China between
2008 and 2009. All isolates were analysed by a combination of
different genotyping methods, including MLST, SCCmec type, and
spa typing, pvl gene was also detected.
In all of the CA-MRSA isolates, twelve STs were obtained, and
ST59 (58.6%) was the most prevalent type throughout China.
SCCmec type IV (67.7%) was the most popular type, and sub-
types IVa, IVc, IVg were found in 77.6%, 11.9%, 2.9% of those
isolates respectively. Eleven spa types were identiﬁed, and four
new spa types were ﬁrstly registered on the net in our ﬁndings.
ST59-SCCmec IVa with t437, was the most prevalent clone. In
addition, 57.6% of those isolates were PVL positive. CA-MRSA iso-
lates were found to be resistant to non-β-lactam antimicrobial,
and multidrug resistance was observed in 85.9% of them.
In conclusion, the recent increase in CA-MRSA infections in
children of China is largely associated with the spread of the
ST59-SCCmec IVa with t437 clone and the multiresistant rate is
high.
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Fibrosis is a frequent, life-threatening complication of most
chronic liver diseases. Up to now liver biopsy is still the gold stan-
dard for assessment of hepatic ﬁbrosis and cirrhosis. However, it
is invasive with possible complications, costly and afﬂicted with
a high degree of sampling error. There is a strong demand for
reliable, liver speciﬁc, non-invasive biomarkers of ﬁbrosis and
cirrhosis to replace or to complement the invasivemethod of nee-
dle biopsy. Class I biomarkers are deﬁned as serum components
which reﬂect ECM turnover (ﬁbrogenesis and ﬁbrolysis) and ﬁ-
brogenic cell changes, mainly of hepatic stellate cells, which are
the dominant proﬁbrogenic cell type in liver. The development of
hepatic ﬁbrosis or cirrhosis is due to increased synthesis, depo-
sition, and possibly reduced degradation of hepatic extracellular
matrix components, especially collagens, such as interstitial type
I and III, basement membrane type IV, microﬁbrillar type VI, and
pericellular type V, non-collagenous proteins, such as laminin,
ﬁbronectin, undulin, etc. Class II biomarkers comprise in general
rather simple standard laboratory tests, which are grouped into
panels. Class II biomarkers are based on algorithmic evaluation
of commonly observed functional alterations of the liver that
do not necessarily reﬂect ECM metabolism and/or ﬁbrogenic
cell changes. About 20 numerical scores or indices are reported
for parameters, which are mostly routine laboratory tests and
frequently multiparametric (panels). They fulﬁl most criteria for
detection and staging of ﬁbrosis and to a lesser extent grading of
ﬁbrogenic activity. The Fibrotest is the most investigated com-
bination of serum markers for ﬁbrosis. However, the diagnostic
use of many of these scores is still limited and standardization
of the assays is only partially realized. Transient elastography
(Fibroscan), which measures the stiffness of the liver by means
of ultrasound as a measure of ﬁbrosis and cirrhosis, is simple to
perform and the inter- and intra-observer variability is small. The
accuracy is high in discriminating between cirrhosis and ﬁbrosis,
but lower for discriminating between the different stages of
ﬁbrosis in both chronic hepatitis B and C. All the makers of liver
ﬁbrosis can be combined for a better diagnosis.
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Background: Spontaneous bacterial peritonitis (SBP) is a major
cause of morbidity and mortality in cirrhosis patients. Gram neg-
ative bacilli, such as Escherichia coli and Klebsiella species (EK)
are the most common cause of SBP. Recently, infections due to
antibiotic-resistant microorganism have increased, especially by
extended-spectrum β-lactamase-producing EK (ESBL-EK). How-
ever, among SBP in patients with advanced liver cirrhosis, the
impacts of antibiotic-resistant (including ESBL-producing) organ-
isms on clinical outcome and risk factors for infection have not
been well focused.
Aims & Methods: Electronic searches in MEDLINE and EMBASE
about SBP in patients with advanced liver cirrhosis were per-
formed to elucidate clinical implications of SBP due to antibiotic-
resistant microorganism.
Results: SBP due to microorganism which was resistant to third
generation cephalosporin accounted for 5∼15%. SBP due to
antibiotic-resistant organism had poorer outcome than SBP by
antibiotic-susceptible strain. Especially, 30-day mortality of SBP
due to ESBL-EK was very high (about 50%). And the risk factors for
the development of infection with antibiotic-resistant organisms
that have been listed in several studies are: underlying severe
hepatic dysfunction, nosocomial infection, longer hospital stay
and ICU stay, presence of indwelling vascular catheter, prior
administration of an antibiotic and higher severity of illness.
Although the impact of a delay in effective initial treatment
was controversial, several studies suggest that ineffective initial
therapy may be a cause of the higher mortality.
Conclusions: SBP due to antibiotic-resistant organism had higher
mortality than SBP by susceptible strain and ineffective initial
therapy may be a cause of the higher rates of treatment failure
and mortality. Therefore, it would seem reasonable to treat
patients with SBP due to antibiotic-resistant organism with ef-
fective antibiotics straight away. However, the injudicious use of
broad antimicrobial regimens is likely to result in further emer-
gence of resistance. To promote the prudent use of antimicrobial
agents, we need further efforts to identify the risk factors for
antibiotic-resistant infection.
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The introduction of the 7-valent (types 4, 6B, 9V, 14, 18C, 19F
and 23F) pneumococcal conjugate vaccine has brought a signif-
icant reduction in invasive pneumococcal disease in the United
States and Europe. In the ≤ 2 years old, the incidence of pneu-
mococcal bacteraemia has decreased from 188 to 59/100,000
